Mycophenolsäure Accord (Mycophenolic Acid)

Mycophenolic acid blocks the enzyme inosine monophosphate dehydrogenase (IMPDH), which is essential for making guanosine nucleotides. Lymphocytes depend on this pathway for DNA synthesis, so inhibition reduces their proliferation and limits the immune response that leads to graft rejection or autoimmune inflammation.

The specific dose of Mycophenolsäure Accord is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and other individual factors. Healthcare professionals adjust the regimen to achieve the desired immunosuppressive effect while minimizing adverse reactions.

Safety data for mycophenolic acid in pregnancy and lactation are limited, and the drug may pose risks to the fetus or infant. It is generally advised to avoid use during pregnancy and while breastfeeding unless the potential benefit outweighs the risk, and only under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mycophenolic acid differs from calcineurin inhibitors such as cyclosporine or tacrolimus by targeting nucleotide synthesis rather than calcineurin signaling. This distinct mechanism can offer a complementary or alternative option, often with a different side‑effect profile, making it useful in combination regimens or for patients intolerant to other agents.

Mycophenolsäure Accord should be stored at room temperature, below 25 °C, in its original container. Keep the product away from moisture, direct sunlight, and extreme temperatures to maintain stability and potency throughout its shelf life.

The medication is taken orally, usually with food or a glass of water to reduce gastrointestinal irritation. The exact dosing schedule—such as once or twice daily—must be prescribed by a qualified healthcare professional based on the individual treatment plan.

Serious risks include severe infections due to immune suppression, bone‑marrow suppression leading to pancytopenia, liver injury, and rare neurological complications such as progressive multifocal leukoencephalopathy (PML). Patients should be monitored regularly for signs of infection, blood‑cell abnormalities, and hepatic dysfunction.

Patients with known hypersensitivity to mycophenolic acid or any component of the formulation should avoid the drug. It is also contraindicated in individuals with uncontrolled severe infections, active malignancy, or those receiving live vaccines, unless the prescriber determines that benefits outweigh the risks.